MX369989B - Inhibidores de serina/treonina cinasa para el tratamiento de enfermedades hiperproliferativas. - Google Patents
Inhibidores de serina/treonina cinasa para el tratamiento de enfermedades hiperproliferativas.Info
- Publication number
- MX369989B MX369989B MX2015002508A MX2015002508A MX369989B MX 369989 B MX369989 B MX 369989B MX 2015002508 A MX2015002508 A MX 2015002508A MX 2015002508 A MX2015002508 A MX 2015002508A MX 369989 B MX369989 B MX 369989B
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- carcinoma
- hyperproliferative
- serine
- diseases
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 title 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 230000003463 hyperproliferative effect Effects 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 201000009030 Carcinoma Diseases 0.000 abstract 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 abstract 1
- 208000003200 Adenoma Diseases 0.000 abstract 1
- 206010001233 Adenoma benign Diseases 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 abstract 1
- 208000017604 Hodgkin disease Diseases 0.000 abstract 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 abstract 1
- 206010023347 Keratoacanthoma Diseases 0.000 abstract 1
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010029260 Neuroblastoma Diseases 0.000 abstract 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000015634 Rectal Neoplasms Diseases 0.000 abstract 1
- 206010038389 Renal cancer Diseases 0.000 abstract 1
- 206010039491 Sarcoma Diseases 0.000 abstract 1
- 208000024313 Testicular Neoplasms Diseases 0.000 abstract 1
- 206010057644 Testis cancer Diseases 0.000 abstract 1
- 208000024770 Thyroid neoplasm Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 201000010536 head and neck cancer Diseases 0.000 abstract 1
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 201000010982 kidney cancer Diseases 0.000 abstract 1
- 208000003849 large cell carcinoma Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 201000005249 lung adenocarcinoma Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 201000010198 papillary carcinoma Diseases 0.000 abstract 1
- 206010038038 rectal cancer Diseases 0.000 abstract 1
- 201000001275 rectum cancer Diseases 0.000 abstract 1
- 201000000849 skin cancer Diseases 0.000 abstract 1
- 208000000649 small cell carcinoma Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 201000003120 testicular cancer Diseases 0.000 abstract 1
- 201000002510 thyroid cancer Diseases 0.000 abstract 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 abstract 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261693671P | 2012-08-27 | 2012-08-27 | |
| PCT/US2013/056876 WO2014036015A1 (en) | 2012-08-27 | 2013-08-27 | Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015002508A MX2015002508A (es) | 2015-10-12 |
| MX369989B true MX369989B (es) | 2019-11-27 |
Family
ID=49118823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015002508A MX369989B (es) | 2012-08-27 | 2013-08-27 | Inhibidores de serina/treonina cinasa para el tratamiento de enfermedades hiperproliferativas. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9388171B2 (https=) |
| EP (1) | EP2888247B1 (https=) |
| JP (1) | JP6378182B2 (https=) |
| KR (1) | KR20150047597A (https=) |
| CN (1) | CN105143200B (https=) |
| AR (1) | AR092253A1 (https=) |
| BR (1) | BR112015004548A2 (https=) |
| CA (1) | CA2882750A1 (https=) |
| HK (1) | HK1210174A1 (https=) |
| MX (1) | MX369989B (https=) |
| RU (1) | RU2644947C2 (https=) |
| TW (1) | TW201408658A (https=) |
| WO (1) | WO2014036015A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2681215B1 (en) | 2011-02-28 | 2015-04-22 | Array Biopharma, Inc. | Serine/threonine kinase inhibitors |
| US9187462B2 (en) | 2011-08-04 | 2015-11-17 | Array Biopharma Inc. | Substituted quinazolines as serine/threonine kinase inhibitors |
| DK2820009T3 (en) | 2012-03-01 | 2018-04-16 | Array Biopharma Inc | Serine / threonine kinase inhibitors |
| TWI616430B (zh) * | 2012-07-27 | 2018-03-01 | 百健Ｍａ公司 | Ａｔｘ調節劑 |
| MX2015004615A (es) | 2012-10-16 | 2015-07-17 | Hoffmann La Roche | Inhibidores de serina/treonina cinasa. |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| CN106029672B (zh) | 2013-12-06 | 2019-03-29 | 基因泰克公司 | 丝氨酸/苏氨酸激酶抑制剂 |
| JP6642942B2 (ja) | 2013-12-30 | 2020-02-12 | アレイ バイオファーマ、インコーポレイテッド | セリン／トレオニンキナーゼ阻害剤 |
| BR112016015235A2 (pt) | 2013-12-30 | 2017-08-08 | Genentech Inc | Composto, composição farmacêutica, método de inibição da atividade da proteína quinase erk e método de tratamento |
| US9879029B2 (en) * | 2014-12-22 | 2018-01-30 | Eli Lilly And Company | ERK inhibitors |
| KR20180134347A (ko) | 2016-04-15 | 2018-12-18 | 제넨테크, 인크. | 암의 진단 및 치료 방법 |
| CN106749117B (zh) * | 2016-11-29 | 2018-10-09 | 北京怡力生物科技有限公司 | 一种3-氨基甲基四氢呋喃的制备方法 |
| EP3601259B1 (en) | 2017-03-30 | 2022-02-23 | F. Hoffmann-La Roche AG | Isoquinolines as inhibitors of hpk1 |
| EP3640242B1 (en) * | 2017-06-16 | 2023-04-19 | Hitgen Ltd. | Rock-inhibiting compound and uses thereof |
| KR102811888B1 (ko) | 2017-09-08 | 2025-05-27 | 에프. 호프만-라 로슈 아게 | 암의 진단 및 치료 방법 |
| EP3752200A1 (en) | 2018-02-13 | 2020-12-23 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| CN108558869B (zh) * | 2018-05-10 | 2019-04-09 | 西安培华学院 | 用于治疗肝癌的化合物及其制剂 |
| TW202019905A (zh) | 2018-07-24 | 2020-06-01 | 瑞士商赫孚孟拉羅股份公司 | 異喹啉化合物及其用途 |
| TW202024053A (zh) | 2018-10-02 | 2020-07-01 | 美商建南德克公司 | 異喹啉化合物及其用途 |
| US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
| CU20210080A7 (es) | 2019-04-02 | 2022-05-11 | Array Biopharma Inc | Triazinas sustituidas como inhibidores de proteína tirosina fosfatasa |
| US20220389009A1 (en) * | 2019-10-01 | 2022-12-08 | Goldfinch Bio, Inc. | Substituted 1,6-naphthyridine inhibitors of cdk5 |
| US12570640B2 (en) | 2020-09-02 | 2026-03-10 | Merck Sharp & Dohme Llc | 2-aminoquinazolines as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995009847A1 (en) | 1993-10-01 | 1995-04-13 | Ciba-Geigy Ag | Pyrimidineamine derivatives and processes for the preparation thereof |
| WO1995009851A1 (en) | 1993-10-01 | 1995-04-13 | Ciba-Geigy Ag | Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| EP0948496A2 (en) | 1996-12-05 | 1999-10-13 | Amgen inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
| GB9812683D0 (en) * | 1998-06-12 | 1998-08-12 | Smithkline Beecham Plc | Novel compounds |
| US6602872B1 (en) | 1999-12-13 | 2003-08-05 | Merck & Co., Inc. | Substituted pyridazines having cytokine inhibitory activity |
| WO2001062233A2 (en) | 2000-02-25 | 2001-08-30 | F. Hoffmann La Roche Ag | Adenosine receptor modulators |
| AU5260601A (en) | 2000-04-26 | 2001-11-07 | Eisai Co Ltd | Medicinal compositions promoting bowel movement |
| WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| JP4606161B2 (ja) | 2002-05-21 | 2011-01-05 | アムジエン・インコーポレーテツド | 置換複素環式化合物および使用方法 |
| US7208498B2 (en) | 2002-07-15 | 2007-04-24 | Merck & Co., Inc. | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
| TW200533357A (en) | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
| CA2561895A1 (en) | 2004-04-13 | 2005-10-27 | Icagen, Inc. | Polycyclic pyrimidines as potassium ion channel modulators |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| JP2008510766A (ja) | 2004-08-27 | 2008-04-10 | ゲーペーツェー ビオテック アーゲー | ピリミジン誘導体 |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
| TW200716594A (en) | 2005-04-18 | 2007-05-01 | Neurogen Corp | Substituted heteroaryl CB1 antagonists |
| US7572809B2 (en) * | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
| JP2009528280A (ja) | 2006-02-16 | 2009-08-06 | シェーリング コーポレイション | Ｅｒｋインヒビターとしてのピロリジン誘導体 |
| CA2651072A1 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| DE102006035202A1 (de) | 2006-07-29 | 2008-01-31 | Lanxess Deutschland Gmbh | Konservierungsmittel auf Basis von Carbonsäureanhydriden |
| TWI389899B (zh) * | 2006-08-08 | 2013-03-21 | Msd Oss Bv | 具口服活性之凝血酶抑制劑 |
| CN101528729A (zh) | 2006-08-23 | 2009-09-09 | 辉瑞产品公司 | 作为gsk-3抑制剂的嘧啶酮化合物 |
| WO2008039882A1 (en) | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
| CN101568529A (zh) | 2006-12-22 | 2009-10-28 | 诺瓦提斯公司 | 作为cdk抑制剂、用于治疗癌症、炎症和病毒感染的杂芳基-杂芳基化合物 |
| JP5611826B2 (ja) | 2007-09-04 | 2014-10-22 | ザ スクリプス リサーチ インスティテュート | タンパク質キナーゼ阻害剤としての置換されたピリミジニル−アミン |
| AU2008324833A1 (en) | 2007-11-06 | 2009-05-14 | E. I. Du Pont De Nemours And Company | Fungicidal heterocyclic amines |
| WO2009146034A2 (en) | 2008-03-31 | 2009-12-03 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors and methods of use thereof |
| US9187426B2 (en) | 2008-06-27 | 2015-11-17 | Novartis Ag | Organic compounds |
| NZ603525A (en) | 2008-06-27 | 2015-02-27 | Celgene Avilomics Res Inc | Pyrimidine based compound and uses thereof |
| ES2548882T3 (es) | 2008-12-08 | 2015-10-21 | Arena Pharmaceuticals, Inc. | Moduladores del receptor de prostaciclina (PGl2) útiles para el tratamiento de trastornos relacionados con los mismos |
| EP2681215B1 (en) | 2011-02-28 | 2015-04-22 | Array Biopharma, Inc. | Serine/threonine kinase inhibitors |
| US9187462B2 (en) * | 2011-08-04 | 2015-11-17 | Array Biopharma Inc. | Substituted quinazolines as serine/threonine kinase inhibitors |
| DK2820009T3 (en) | 2012-03-01 | 2018-04-16 | Array Biopharma Inc | Serine / threonine kinase inhibitors |
-
2013
- 2013-08-27 TW TW102130680A patent/TW201408658A/zh unknown
- 2013-08-27 MX MX2015002508A patent/MX369989B/es active IP Right Grant
- 2013-08-27 CA CA2882750A patent/CA2882750A1/en not_active Abandoned
- 2013-08-27 HK HK15111084.7A patent/HK1210174A1/xx unknown
- 2013-08-27 AR ARP130103040A patent/AR092253A1/es unknown
- 2013-08-27 EP EP13759395.0A patent/EP2888247B1/en active Active
- 2013-08-27 JP JP2015529957A patent/JP6378182B2/ja active Active
- 2013-08-27 BR BR112015004548A patent/BR112015004548A2/pt not_active IP Right Cessation
- 2013-08-27 CN CN201380051518.1A patent/CN105143200B/zh active Active
- 2013-08-27 RU RU2015110985A patent/RU2644947C2/ru not_active IP Right Cessation
- 2013-08-27 KR KR1020157007729A patent/KR20150047597A/ko not_active Withdrawn
- 2013-08-27 WO PCT/US2013/056876 patent/WO2014036015A1/en not_active Ceased
- 2013-08-27 US US14/011,501 patent/US9388171B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9388171B2 (en) | 2016-07-12 |
| CN105143200B (zh) | 2018-10-16 |
| RU2015110985A (ru) | 2016-10-20 |
| BR112015004548A2 (pt) | 2017-08-08 |
| US20140066453A1 (en) | 2014-03-06 |
| KR20150047597A (ko) | 2015-05-04 |
| WO2014036015A1 (en) | 2014-03-06 |
| AR092253A1 (es) | 2015-04-08 |
| TW201408658A (zh) | 2014-03-01 |
| CA2882750A1 (en) | 2014-03-06 |
| HK1210174A1 (en) | 2016-04-15 |
| EP2888247A1 (en) | 2015-07-01 |
| CN105143200A (zh) | 2015-12-09 |
| RU2644947C2 (ru) | 2018-02-15 |
| JP6378182B2 (ja) | 2018-08-22 |
| EP2888247B1 (en) | 2020-03-25 |
| MX2015002508A (es) | 2015-10-12 |
| JP2015526519A (ja) | 2015-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015002508A (es) | Inhibidores de serina/treonina cinasa para el tratamiento de enfermedades hiperproliferativas. | |
| MY170904A (en) | Ret inhibitor | |
| AU2015314007B2 (en) | Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers | |
| PH12017501766B1 (en) | Heterocyclylamines as pi3k inhibitors | |
| PH12015502814A1 (en) | 4-membered ring carboxamides used as nematicides | |
| EA201890730A1 (ru) | Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования | |
| PH12015501221A1 (en) | Pyrimidinones as pi3k inhibitors | |
| EA201491595A1 (ru) | Азотсодержащее ароматическое гетероциклическое соединение | |
| MX350539B (es) | Compuestos de enediino, conjugados de los mismos y sus usos y metodos. | |
| UA112795C2 (uk) | Біциклічні піразинонові похідні | |
| MX2018004832A (es) | Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer. | |
| MX2014002208A (es) | Inhibidores de serina/treonina quinasa. | |
| NZ628296A (en) | Compositions and methods of use of phorbol esters | |
| MY201673A (en) | Polycyclic amide derivatives as cdk9 inhibitors | |
| MD20150071A2 (ro) | Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni | |
| PH12016501071A1 (en) | Serine/threonine kinase inhibitors | |
| NZ627480A (en) | Inhibitors of iap | |
| MX2016008259A (es) | Metodo de proceso para inhibidores de fosfatidilinositol 3-cinasa. | |
| MX2016001641A (es) | Ciclobutilcarboxamidas como nematicidas. | |
| PH12015502757A1 (en) | Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor | |
| MX2016007810A (es) | Derivados de n1-(3,3,3-trifluoro-2-hidroxo-2-metilpropionil)-piper idina como inhibidores de piruvato deshidrogenasa cinasa. | |
| MX364859B (es) | Derivados de imidazopirazinona. | |
| MX2015011660A (es) | Derivados der 6-[4-(1h-imidazol-2-il)piperidin-1-il]pirimidin-4-am ina como moduladores de la actividad de cinasa. | |
| WO2012166463A3 (en) | Aminooxazole inhibitors of cyclin dependent kinases | |
| NZ714625A (en) | Kinase inhibitors for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |